How are the FDA discussions going?
What are the prospects of gaining fast track status?
What revenue forecasts are available upon doing so?
Is there a marketing agreement in place for distribution of the product if they have moved to commercial production?
What is the NTA if the CBio deal is taken in to consideration?
Why is this company so intent on denying the market information to ascribe an appropriate value on?
It goes on and on and on. Nothing doing til Pfizer wants to make its move.
Add to My Watchlist
What is My Watchlist?